Big Pharma 1Q China Growth Roundup: The Winner Is…
This article was originally published in PharmAsia News
Executive Summary
The first quarter of 2015 was marked by a further slowing down in China’s economy, lingering compliance shadows and mounting pricing pressures, which have dampened hope for a quick recovery and caused top multinational pharma executives to voice caution and moderate growth targets.